| Downregulation of TAP1 and TAP2 in early stage breast cancer AM Henle, A Nassar, D Puglisi-Knutson, B Youssef, KL Knutson PloS one 12 (11), e0187323, 2017 | 52 | 2017 |
| Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system CL Erskine, AM Henle, KL Knutson JoVE (Journal of Visualized Experiments), e3683, 2012 | 42 | 2012 |
| Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology DE Perez, AM Henle, A Amsterdam, HR Hagen, JA Lees Pigment cell & melanoma research 31 (5), 604-613, 2018 | 33 | 2018 |
| Increase in SARS-CoV-2 RBD-specific IgA and IgG antibodies in human milk from lactating women following the COVID-19 booster vaccination AM Henle Journal of Human Lactation 39 (1), 51-58, 2023 | 17 | 2023 |
| Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells AM Henle, CL Erskine, LM Benson, R Clynes, KL Knutson The Journal of Immunology 190 (1), 479-488, 2013 | 10 | 2013 |
| Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide KL Knutson, AM Henle US Patent 10,117,919, 2018 | 4 | 2018 |
| The development of pigmentation in new tissue arises from precursor and not migratory melanocytes in a transgenic GNAQQ209L zebrafish model of uveal melanoma AM Henle, J Muske, M Poplawski, T Perlmutter Investigative Ophthalmology & Visual Science 59 (9), 3177-3177, 2018 | 1 | 2018 |
| Oncogenic GNAQ and GNA11 drive tumorigenesis and hyper‐pigmentation in a zebrafish model of human uveal melanoma A Henle, E Hoelzli, D Perez, A Amsterdam, J Lees The FASEB Journal 29, LB144, 2015 | 1 | 2015 |
| Development of an undergraduate cell biology laboratory to assess pigmentation and cell size in a zebrafish model of uveal melanoma AM Henle Zebrafish 21 (2), 137-143, 2024 | | 2024 |
| Métodos y materiales para generar células T CD8+ con la capacidad para reconocer células cancerígenas que expresen un polipéptido HER2/neu KL Knutson, AM HENLE | | 2018 |
| Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide KL Knutson, AM Henle US Patent 9,814,767, 2017 | | 2017 |
| Identification of HER-2/neu peptide p373-382 as a naturally processed immunodominant HLA-A2 binding epitope (46.11) A Henle, C Erskine, L Benson, K Knutson The Journal of Immunology 188 (1_Supplement), 46.11-46.11, 2012 | | 2012 |
| Class I antigen processing and presentation in breast cancer AM Henle College of Medicine-Mayo Clinic, 2012 | | 2012 |
